The prognostic significance of indium-111-capromab penetide

Journal of Clinical Oncology

Volumn 22, Issue 2, 2004, Pages 379-380

  Sodee, D B ^a   Faulhaber, P F ^a   Nelson, A D ^a   Bakale, G ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPROMAB PENDETIDE; DIAGNOSTIC AGENT; INDIUM; MONOCLONAL ANTIBODY;

COMPUTER ASSISTED TOMOGRAPHY; HUMAN; MALE; NOTE; PREDICTION AND FORECASTING; PROGNOSIS; PROSTATE TUMOR; REPRODUCIBILITY; SCINTISCANNING; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL; HUMANS; INDIUM RADIOISOTOPES; MALE; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 1342289770     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2004.99.163     Document Type: Letter

References (5)

1. Thomas CT, Bradshaw PT, Pollock BH, et al: Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 21: 1715-1721, 2003
2. Sodee DB, Malguria N, Faulhaber P, et al: Multi-center ProstaScint findings in 2154 patients with prostate cancer. Urology 56: 988-993, 2000
3. Kahn D, Williams RD, Hasemann MK, et al: Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed prostatectomy. J Clin Oncol 16: 284-289, 1998
4. Levesque PE, Nieh PT, Zinman LN, et al: Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy. Urology 51: 978-984, 1998
5. Sodee DB, Conant R, Chalfant M, et al: Preliminary imaging results utilizing indium-111 labeled CYT-356 (ProstaScint®) in the detection of recurrent prostate carcinoma. Clin Nucl Med 21: 759-767, 1996